Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on Artivion and keeping the price target at $51.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
William Plovanic has given his Buy rating due to a combination of factors highlighting Artivion’s growth potential and strategic initiatives. The company’s AMDS product is expected to drive significant long-term growth, leveraging its unique market position with limited competition and its potential to expand treatment options for acute Type A dissections. Management’s approach of targeting high-volume centers and gradually onboarding accounts illustrates a clear multi-year scaling strategy, emphasizing the product’s commercial and utilization outlook.
Plovanic also pointed to the strength and reacceleration of Artivion’s On-X mechanical valve business, backed by newly published clinical studies emphasizing its benefits over bioprosthetic alternatives for younger patients. These studies are projected to expand the total addressable market by $100M in the U.S. Additionally, the company’s financial health, conservative guidance, and anticipated strategic moves like the potential Endospan acquisition further cement management’s vision for long-term value creation. Taken together, these factors underscore Plovanic’s confidence in Artivion’s ability to outperform, reaffirming the Buy rating and $51 price target.
AORT’s price has also changed dramatically for the past six months – from $28.730 to $45.910, which is a 59.80% increase.